Abstracts Archive - Page 2259 of 2607 - ACR Meeting Abstracts

Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Mitsuhiro Takeno¹, Kayo Terauchi¹, Yohei Kirino^1,2, Ryusuke Yoshimi¹, Nobuhisa Mizuki², Etsuko Shibuya³ and Yoshiaki Ishigatsubo², ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…
Abstract Number: 2629 • 2013 ACR/ARHP Annual Meeting
Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet’s Disease ?
Fatma Alibaz-Oner¹, Gonca Mumcu², Zeynep Kubilay³, Gülsen Ozen⁴, Gülce Celik³, Aslı Karadeniz³, Meryem Can⁵, Sibel Yılmaz Oner¹, Nevsun Inanc⁶, Pamir Atagunduz⁷, Tülin Ergun⁸ and Haner Direskeneli¹, ¹Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ²Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ³Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey, ⁴Rheumatology, Marmara University School of Medicine., Istanbul, Turkey, ⁵Department of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁶Marmara University School of Medicine, Istanbul, Turkey, ⁷Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁸Dermatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: The clinical course of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing nature is unsufficiently explored. As complete remission should be aimed…
Abstract Number: 2630 • 2013 ACR/ARHP Annual Meeting
Low Medication Adherence Is Observed In Behcet’s Disease
Gonca Mumcu¹, Ali Taze², Esra Kula², Semiha Yemez², Silay Eksi², Leyla Köksal³, Fatma Alibaz-Oner⁴, Sibel Yilmaz Oner⁴, Pamir Atagündüz⁴, Nevsun Inanc⁵, Tülin Ergun⁶ and Haner Direskeneli⁴, ¹Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ²Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ³Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁶Dermatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Symptom-control with reduction of mortality and morbidityare the main treatment goalsin Behcet’s Disease (BD). However, similar to other chronic disorders, increased unnecessary visits, hospitalisation…
Abstract Number: 2631 • 2013 ACR/ARHP Annual Meeting
Fertility In Behçet’s Syndrome: Structured Interview In A Multidisciplinary Center
Caner Saygin¹, Didem Uzunaslan¹, Gulen Hatemi², Koray Tascilar¹ and Hasan Yazici³, ¹University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ²Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, ³Cerrahpasa Medical Faculty University of Istanbul, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey
Background/Purpose: Behçet’s Syndrome (BS) follows an active course during the child-bearing years in both men and women. Whether fertility is decreased among the BS patients…
Abstract Number: 2632 • 2013 ACR/ARHP Annual Meeting
Long Term Outcome Of Neuro-Behçet’s Disease
Nicolas Noel¹, Remy Bernard², Bertrand Wechsler³, Matthieu Resche-Rigon², Du Boutin⁴, Jean-Charles Piette⁵, Aurélie Drier⁶, Didier Dormont⁶, Patrice Cacoub⁴ and David Saadoun⁷, ¹APHP, Hopital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France, ²Biostatistics, Hopital Saint-Louis, Paris, France, ³Internal Medecine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ⁶Neuroradiology, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose: Neurological involvement occurs in 5.3 to up to 59% of patients with Behçet’s disease (BD). Although the clinical and imaging features of neuro-Behçet’s disease…
Abstract Number: 2633 • 2013 ACR/ARHP Annual Meeting
Clinical Spectrum Of Cutaneous Vasculitis
Javier Loricera¹, Vanesa Calvo-Río¹, Francisco Ortiz-Sanjuan², Héctor Fernández-Llaca³, Marcos A. González-López⁴, Lino Álvarez⁵, M. Carmen González-Vela⁶, Domingo González-Lamuño⁷, Cristina Mata², Javier Rueda-Gotor⁸, Víctor M. Martínez-Taboada⁹, Miguel Angel González-Gay² and Ricardo Blanco¹⁰, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ³Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁴Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁶Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁷Pediatrics, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, ⁸Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ¹⁰Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: Cutaneous vasculitis (CV) encompasses a large and heterogeneous set of syndromes characterized by inflammation of the skin vessels. The most common clinical manifestation is…
Abstract Number: 2634 • 2013 ACR/ARHP Annual Meeting
Henoch-Schönlein Purpura: Clinical Spectrum Of The Disease In 417 Patients From A Single Center
F. Ortiz-Sanjuán¹, Vanesa Calvo-Río², Javier Loricera¹, C Mata¹, L Martín Penagos³, L Alvarez⁴, M. Carmen González-Vela⁵, D González-Lamuño⁴, Javier Rueda-Gotor⁶, Héctor Fernández-Llaca⁷, Marcos A. González-López⁸, Susana Armesto⁹, M. Enriqueta Peiró², M. Arias³, Miguel Angel Gonzalez-Gay¹ and Ricardo Blanco¹⁰, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Nephrology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁴Pediatrics, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁷Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ⁸Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁹Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ¹⁰Hospital Marques de Valdecilla, Santander, Spain
Background/Purpose: The severity of clinical features and the outcome in the different series of Henoch-Schönlein Purpura (HSP) shows great variability, probably due to selection-bias. Our…
Abstract Number: 2595 • 2013 ACR/ARHP Annual Meeting
Microvascular Abnormalities In Patients With Early Systemic Sclerosis: Less Severe Morphological Changes Compared To Patients With Definite Disease
Cintia Camargo, Juliana Sekiyama, Maria I. Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: To analyze the morphological and functional abnormalities of the microcirculation through widefield nailfold capillaroscopy (NFC), videocapillaroscopy and cutaneous microvascular blood flow measurement before and…
Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Bernadette Lynch¹, Henry Penn², Jennifer Harvey³, Aine Burns⁴ and Christopher P. Denton⁵, ¹Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ²Northwick Park Hospital, Harrow, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Nephrology, The Royal Free Hospital, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…
Abstract Number: 2594 • 2013 ACR/ARHP Annual Meeting
Stabilisation Of Microcirculation In Early Systemic Sclerosis Patients With Diffuse Skin Involvement Following Rituximab Treatment
Vanessa Smith¹, Carmen Pizzorni², Valeria Riccieri³, Saskia Decuman⁴, Yves P. Piette¹, Ellen Deschepper⁵, Filip De Keyser¹ and Maurizio Cutolo⁶, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Department of Internal Medicine and Medical Specialities, University Sapienza, Rome, Italy, ⁴Department of Internal Medicine, Ghent University, Ghent, Belgium, ⁵Biostatistics Unit, Department of Public Health, Ghent University, Ghent, Belgium, ⁶University of Genova, Genova, Italy
Background/Purpose: Microangiopathy in systemic sclerosis is progressive over time [1, 2]. This study assesses microangiopathic evolution by nailfold videocapillarocopic (NVC) analysis after two treatment course…
Abstract Number: 2596 • 2013 ACR/ARHP Annual Meeting
Association Between Nail Fold Capillaroscopy Abnormalities and Thermographic Assessment Of Peripheral Microvascular Dysfunction In An Unselected Cohort Of Patients Under Investigation For Symptoms Of Raynaud’s Phenomenon
Bhavisha Vasta¹, Marina Scolnik^1,2, Darren Hart¹, Jacqueline A. Shipley¹, Sue Brown¹, Eleanor Korendowych¹, Neil J McHugh^1,3 and John D. Pauling^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Nail fold capillaroscopy (NC) and infrared thermography (IRT) allow objective assessment of digital microvascular abnormalities in patients with Raynaud’s phenomenon (RP) and have an…
Abstract Number: 2597 • 2013 ACR/ARHP Annual Meeting
Acupressure For The Treatment Of Raynaud’s Phenomenon: A Pilot Randomized Controlled Trial
Heather Gladue¹, Richard E. Harris², Veronica Berrocal³, Pei-Suen Tsou⁴, Gautam Edhayan⁵, Ray Ohara⁵ and Dinesh Khanna⁶, ¹University of Michigan, Ann Arbor, MI, ²Anesthesiology, University of Michigan, Ann Arbor, MI, ³Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵University of Michigan Medical School, Ann Arbor, MI, ⁶Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Raynaud’s phenomenon (RP) affects approximately 10% of the US population. The high cost, lack of efficacy, and side effects of conventional medical therapies necessitates…
Abstract Number: 2598 • 2013 ACR/ARHP Annual Meeting
Timing and Outcome Of Transition From Primary To Secondary Raynaud’s Phenomenon: A Capillaroscopic Based Study
Alberto Sulli¹, Giorgia Ferrari², Elena Bernero², Carmen Pizzorni², Vanessa Smith³, Barbara Ruaro² and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁴Internal medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy
Background/Purpose: Raynaud's phenomenon (RP) is classified as primary (PRP) or secondary (SRP) depending on its association with an underlying disease (1,2). PRP can evolve to…
Abstract Number: 2599 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Mycophenolate In Systemic Sclerosis: A Systemic Review
Mohammed Omair¹, Abdulaziz Alahmadi² and Sindhu R. Johnson³, ¹Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Scleroderma Research Program, Division of Rheumatology, Mount Sinai Hospital, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ³Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Mycophenolate reduces chronic allograft nephropathy and interstitial fibrosis by inhibiting TGF-β, which is an important molecule in the pathogenesis of systemic sclerosis (SSc). The…
Abstract Number: 2600 • 2013 ACR/ARHP Annual Meeting
Shear Wave Elastography: A Novel Quantitative Approach For Evaluating Scleroderma Skin
Ingeborg Sacksen¹, Mark H. Wener², P. Scott Pollock³ and Manjiri K. Dighe⁴, ¹Rheumatology, University of Washington, Seattle, WA, ²Rheumatology & Lab Med, University of Washington, Seattle, WA, ³Internal Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ⁴Radiology, University of Washington, Seattle, WA
Background/Purpose: Systemic sclerosis (SSc) is a multi-system disease with both visceral and cutaneous fibrosis. Dermal elasticity is reduced and stiffness increased due to excessive dermal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].